

#3

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-289US

In Re Application Of: MEHTA et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/540,245	12/23/2002	TBA	026815	TBA	

Title:

1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-289US

In Re Application of: **MEHTA et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/540,245	12/23/2002	TBA	026815	TBA	

Title:

1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912
as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
_____ (Date)
_____ Signature of Person Mailing Correspondence
_____ Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: February 7, 2006

Kenneth Y. Lo
Reg. No. 51,961
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Tel.: (609) 720-8055
Fax: (609) 514-9779

CC:

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-289US

Serial No.: 10/540,245

Applicants: MEHTA *et al.*

Filed: 6/22/2005

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	2,956,062	10/11/1960	Lunsford	260	326.3	
	A2	3,091,570	5/28/1963	Biel	167	65	
	A3	3,176,019	3/30/1965	Campbell <i>et al.</i>	260	293.4	
	A4	5,281,601	1/25/1994	Cross <i>et al.</i>	514	320	
	A5	5,948,792	9/7/1999	Tsuchiya <i>et al.</i>	514	317	
	A6	6,130,232	10/10/2000	Mase <i>et al.</i>	514	318	
	A7	6,174,900	1/16/2001	Okada <i>et al.</i>	514	317	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	B1	EP 0 012 071	6/11/1980	EPO	C07D	471/10		
	B2	EP 0 325 571	7/26/1989	EPO	C07C	215/54		
	B3	EP 0 388 054	9/19/1990	EPO	C07D	207/08		
	B4	EP 0 801 067	10/15/1997	EPO	C07D	453/02		
	B5	EP 0 823 423	2/11/1998	EPO	C07D	211/46		
	B6	EP 0 863 141	9/9/1998	EPO	C07D	401/06		
	B7	EP 0 930 298	7/21/1999	EPO	C07D	211/46		
	B8	GB 940,540	10/30/1963	UK	C07C			
	B9	JP 135958/1994	5/17/1994	Japan	C07D	333/16	Abstract	
	B10	JP 92921/1994	4/5/1994	Japan	C07C	237/20	Abstract	
	B11	WO 91/09013	6/27/1991	PCT	C07D	207/08		
	B12	WO 93/16018	8/19/1993	PCT	C05F	17/02		
	B13	WO 93/16048	8/19/1993	PCT	C07D	211/26	Equivalent CA 2155320	
	B14	WO 96/33973	10/31/1996	PCT	C07D	211/46	Equivalent EP 0823423	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-289US	Serial No.: 10/540,245
	Applicants: MEHTA <i>et al.</i>	
	Filed: 6/22/2005	Group:

	B15	WO 97/45414	12/4/1997	PCT	C07D	211/58	Abstract
	B16	WO 98/00016	1/8/1998	PCT	A01N	43/38	
	B17	WO 98/00109	1/8/1998	PCT	A61K	9/08	
	B18	WO 98/00132	1/8/1998	PCT	A61K	31/40	
	B19	WO 98/00133	1/8/1998	PCT	A61K	31/40	
	B20	WO 98/05641	2/12/1998	PCT	C07D	211/46	Equivalent US 5,948,792
	B21	WO 98/21183	5/22/1998	PCT	C07D	207/12	Equivalent US 6,307,060
	B22	WO 98/29402	7/9/1998	PCT	C07D	311/20	
	B23	WO 02/04402	1/17/2002	PCT	C07C	219/10	Equivalent US 6,846,835

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Kubo <i>et al.</i> , "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , <u>323</u> (2):411-416 (1986)					
	C2	Bonner <i>et al.</i> , "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , <u>237</u> :527-531 (1987)					
	C3	Eglen <i>et al.</i> , "Muscarinic Receptor Ligands and Their Therapeutic Potential", <i>Current Opinions in Chemical Biology</i> , <u>3</u> (4):426-432 (1999) XP000972296, ISSN: 1367-5931					
	C4	Eglen <i>et al.</i> , "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (8):409-414 (2001)					
	C5	Felder <i>et al.</i> , "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , <u>43</u> (23):4333-4353 (2000)					
	C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , <u>6</u> :142-193 (2001)					
	C7	Birdsall <i>et al.</i> , "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (5):215-219 (2001)					
	C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , <u>41</u> :691-721 (2001)					
	C9	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , <u>2</u> (3):268-282					
	C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , <u>55</u> (Suppl. 5A):33-46 (2000)					
	C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)					

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-289US

Serial No.: 10/540,245

Applicants: MEHTA *et al.*

Filed: 6/22/2005

Group:

- | | |
|-----|---|
| C12 | Sagara <i>et al.</i> , "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M ₃ Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , 45:984-987 (2002) XP002238502, ISSN: 0022-2623 |
| C13 | Moriya <i>et al.</i> , "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , 64(25):2351-2358 (1999) |
| C14 | Cheng and Prusoff, "Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , 22:3099-3108 (1973) |
| C15 | Franko <i>et al.</i> , "Derivatives of 3-Pyrrolidinols-III. The Chemistry, Pharmacology, and Toxicology of some N-Substituted-3-Pyrrolidyl alpha-Substituted Phenylacetates", <i>Journal of Medicinal and Pharmaceutical Chemistry</i> , 2:523-540 (1960) |
| C16 | Biel <i>et al.</i> , "Central Stimulants. II. Cholinergic Blocking Agents", <i>Journal of Organic Chemistry, American Chemical Society</i> , 26, 4096-4103 (1961) |
| C17 | Taniguchi <i>et al.</i> , "Agents for the Treatment of Overactive Detrusor. VI. Synthesis and Pharmacological Properties of Acetamide Derivatives Bearing Cyclic Amines in N-Substituents", <i>Chemical and Pharmaceutical Bulletin</i> , 42(1):74-84 (1994) |
| C18 | O'Neill <i>et al.</i> , "Biochemical effects of psychotomimetic anticholinergic drugs", <i>Advances in Biochemical Psychopharmacology</i> , 6:203-218 (1972) |
| | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.